TFIP11 Antibody

Applications of TFIP11 Antibodies

TFIP11 antibodies are validated for:

Western Blotting (WB)

• Detected in HeLa, LNCaP, MCF-7, HEK-293, and K-562 cells .

• Observed in human testis, brain, liver, prostate, and breast cancer tissues .

Immunohistochemistry (IHC)

• Staining in human breast, prostate, and liver cancer tissues (antigen retrieval recommended with TE or citrate buffer) .

Immunofluorescence (IF)/ICC

• Localized TFIP11 in HeLa cells, confirming nuclear and cytoplasmic distribution .

ELISA

• Used for quantifying TFIP11 levels in human, mouse, and rat samples .

Research Applications and Findings

TFIP11 antibodies have been instrumental in elucidating TFIP11’s roles in:

Replication Fork Reversal and Genome Stability

• Interaction with BLM Complex: Co-immunoprecipitation (Co-IP) assays using anti-TFIP11 antibodies confirmed physical interaction with BLM, TOP3A, RMI1, and RIF1 proteins, enhanced under replication stress (e.g., hydroxyurea treatment) .

• Fork Reversal Defects: TFIP11 depletion reduced reversed forks by ~50%, as visualized via electron microscopy and BrdU immunofluorescence assays .

RNA Splicing and Spliceosome Dynamics

• Spliceosome Disassembly: TFIP11 antibodies identified TFIP11’s role in late-stage splicing by binding to hPrp43 and mediating lariat intron release from spliceosomes .

• Subnuclear Localization: TFIP11 antibodies revealed its presence in TFIP bodies and coilin-containing Cajal bodies, critical for RNA processing .

Technical Considerations

• Validation Data: Proteintech antibodies (e.g., 66114-1-Ig) show specificity in WB and IHC, with minimal cross-reactivity .

• Optimization: Dilution ranges vary by application; titration is recommended for optimal signal-to-noise ratios .